A population-based study of the costs of care for community-acquired pneumonia

European Respiratory Journal

Volumn 23, Issue 4, 2004, Pages 610-616

  Bartolome M ^a   Almirrall, J ^a   Morera, J ^b   Pera, G ^c   Ortun V ^d   Bassa, J ^a   Bolibar I ^e   Balanzo X ^a   Verdaguer, A ^a   de Salas, J M ^a   Costa, J ^a   Tristany, M ^a   Grau, M J ^a   Sancho, S ^a   Miguel, E ^a   Fradera, M ^a   Ochoa, I ^a   Quilez, A ^a   Marina, V ^a   Subias, P ^a   Jimeno, B ^a   Bradnovich, A ^a   Rodriguez, M ^a   Ramon, E ^a   Gardella, A ^a   Gines C ^a   Montero, J C ^a   Flores, P ^a   Serra, P ^a   Torrellas, E ^a   Buxade I ^a   Mussoll, J ^a   Gomez, M ^a   Mestres, X ^a   Armada, A ^a   Mallafre J ^a   Roger, M ^a   Gros, M T ^a   Les, N ^a   Joanola, J ^a   Domenech J ^a   Bundo M ^a   Trilla, Ma ^a   Massons, J ^a   Montero, J ^a   Zurilla, E ^a   Alegre, M ^a   Papiol, M ^a   Marti O ^a   Catala M ^a   Martinez, M A ^a   Diaz, E ^a   Toran P ^a   Aizpurua, M M ^a   Lozano, G ^a   Casals, J ^a   Sorribes, J ^a   Torrellas, D ^a   Casas, A ^a   Bernad, J ^a   de Montoliu, A ^a   Gaya, J ^a   Valles R ^a   Vasquez, A ^a   Peiro, R ^a   Areste G ^a   Mengual, N ^a   Vines M C ^a   Almerich, E ^a   Lopez, M A ^a   Bel, J ^a   Gosalves, A ^a   Macip, S ^a   Carrillo, E ^a   Paulo, P ^a   Pol, M ^a   Sala, J ^a   Mir, P ^a   Anglada, J L L ^a   Salabarnada, J ^a   Sanz, E ^a   Gorgas, F ^a   Ribas, A ^a   Fau, E ^a   Pellicer, I ^a   Morales, S ^a   Burdoy, E ^a   Busquets, L L ^a   de Castro, S ^a   Corona, E ^a   Verde, Y ^a   Borras A ^a   Aznar, F ^a   Riera, F ^a   Vazquez, A ^a   Gil, P ^a   Serra Prat, M ^a   Parra, O ^a   more..

^a Consorci Sanitari de Mataró ^*

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Catalonian Institute of Oncology   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Community acquired pneumonia; Cost reduction; Direct costs; Length of stay; Site of care

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; COMMUNITY-ACQUIRED INFECTIONS; COST SAVINGS; COSTS AND COST ANALYSIS; DIRECT SERVICE COSTS; FEMALE; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT ADMISSION; PNEUMONIA, BACTERIAL; POPULATION SURVEILLANCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SPAIN;

EID: 11144354830     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00076704     Document Type: Article

References (36)

1. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: A population-based study. Eur Respir J 2000; 15: 757-763.
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-988.
3. Lave JR, Fine MJ, Sankey SS, Hanusa BH, Weissfeld LA, Kapoor WN. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med 1996; 11: 415-421.
4. Guest JF, Morris A. Community-acquired pneumonia: The annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534.
5. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837.
6. Muñoz Alcañiz A, Sobrino Vegas L, Velasco Muñoz ML, Cano Portero R, Mateo Ontañón S. Vigilancia de las neumonías en España. Bol Epid Sem 1997; 5: 29-36.
7. Oseasohn R, Skipper BE, Tempest B. Pneumonia in a Najavo community. Am Rev Respir Dis 1978; 11: 1003-1009.
8. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 2: 671-674.
9. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 274: 134-141.
10. Fernández Álvarez R, Gullón Blanco JA, Rubinos Cuadrado G, et al. Neumonía adquirida en la comunidad: Influencia de la duración de la antibioterapia intravenosa en la estancia hospitalaria y relación coste/efectividad. Arch Bronconeumol 2001; 37: 366-370.
11. González-Moraleja J, Sesma P, González C, Lopez ME, Garcia JF, Alvarez-Sala JL. ¿Cuál es el coste de las neumonías que ingresamos inadecuadamente? Arch Bronconeumol 1999; 35: 312-316.
12. Buñuel Álvarez JC, Vila Pablos C, Tresserras González E, et al. Estudio de costes del proceso diagnóstico-terapéutico de la neumonía infantil adquirida en la comunidad en Atención Primaria. Rev Pediatr Aten Primaria 1999; 1: 43-53.
13. Whittle J, Lin CJ, Lave JR, et al. Relationship of provider characteristics to outcomes, process, and costs of care for community-acquired pneumonia. Med Care 1998; 36: 977-987.
14. McCormick D, Fine MJ, Coley CM, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: Are shorter stays associated with worse medical Outcomes? Am J Med 1999; 107: 5-12.
15. Siegel RE. How long a stay in the hospital is needed for patients with community-acquired pneumonia? Am J Med 2000; 109: 434-436.
16. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length or hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109: 378 385.
17. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-755.
18. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996; 110: 965-971.
19. Fine MJ, Singer DE, Phelps AL, Hanusa BH, Kapoor WN. Differences in length of hospital stay in patients with community-acquired pneumonia: A prospective four-hospital Study. Med Care 1993; 31: 371-380.
20. Gertman PM, Restuccia JD. The appropriateness evaluation protocol: A technique for assessing unnecessary days of hospital care. Med Care 1981; 19: 855-871.
21. Cunnha BA. Community-acquired pneumonia. Cost-effective antimicrobial therapy. Postgrad Med 1996; 99: 109-123.
22. Departarnent de Sanitat i Seguretat Social. Decret del 23 de desembre de 1997. DOGC 1997; 2547: 15080-15087.
23. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
24. Bolíbar I, Balanzó X, Armada A, et al. El impacto de la reforma de la atención primaria en la utilización de servicios de urgencias hospitalarios. Med Clin (Barc) 1996; 107: 289-295.
25. Santos de Unamuno C, Llorente San Martín MA, Carandell Jäger E, et al. Lugar de atención, etiología y tratamiento de las neumonías adquiridas en la comunidad de Palma de Mallorca. Med Clin (Barc) 1998; 110: 290-294.
26. Weingarten SR, Riedinger MS, Hobson P, et al. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996; 153: 1110-1115.
27. Macfarlane J. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society study. Semin Respir Infect 1994; 9: 153-165.
28. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278: 32-39.
29. Porath A, Schlaeffer F, Lieberman D. Appropriateness of hospitalization of patients with community-acquired pneumonia. Ann Emerg Med 1996: 27: 176-183.
30. Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med 1998; 104: 17-27.
31. Zalacaín R, Talayero N, Achótegui V, Corral J, Barrena I, Sobradillo V. Neumonía adquirida en la comunidad. Fiabilidad de los criterios para decidir tratamiento ambulatorio. Arch Bronconeumol 1997; 33: 74-79.
32. Dorca J, Bello S, Blanquer J, et al. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol 1997; 33: 240-246.
33. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996; 101: 508-515.
34. Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL. Economic burden of pneumonia in an employed population. Arch Intern Med 2001; 161: 2725-2731.
35. Almirall J, Bolíbar I, Balanzó X, González CA. Risk factors for community-acquired pneumonia in adults: A population-based case-control study. Eur Respir J 1999; 13: 349-355.
36. Cots Reguant F, Castells Oliveres X, García Altés A, Saez Zafra M. Relación de los costes directos de hospitalización con la duración de la estancia. Gac Sanit 1997; 11: 287-295.